Workers Compensation Insurance

Search documents
ProAssurance (PRA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKSยท 2025-08-06 01:01
Core Insights - ProAssurance reported a revenue of $271.94 million for the quarter ended June 2025, reflecting a decrease of 2.4% year-over-year, but exceeding the Zacks Consensus Estimate by 1.96% [1] - The company's EPS was $0.52, significantly higher than the $0.23 reported in the same quarter last year, resulting in an EPS surprise of 173.68% compared to the consensus estimate of $0.19 [1] Financial Performance Metrics - Net Loss Ratio was reported at 68.8%, better than the average estimate of 77% from three analysts [4] - Underwriting Expense Ratio stood at 34.8%, slightly above the average estimate of 33.9% [4] - Combined Ratio was 103.6%, outperforming the average estimate of 110.9% [4] - Net premiums earned totaled $232.41 million, surpassing the average estimate of $225.22 million, but showing a year-over-year decline of 3.1% [4] - Net investment income was $38.93 million, exceeding the average estimate of $37.5 million, with a year-over-year increase of 6.5% [4] - Equity in earnings of unconsolidated subsidiaries was $4.58 million, compared to the average estimate of $3.07 million, reflecting a 47% decrease year-over-year [4] - Other income was reported at $0.6 million, significantly lower than the average estimate of $2.68 million, marking a 71.5% decline year-over-year [4] Segment Performance - Net Premiums Earned in Specialty Property & Casualty was $179.31 million, slightly below the average estimate of $180.34 million, with a year-over-year decrease of 2.8% [4] - Net Premiums Earned in Segregated Portfolio Cell Reinsurance was $11.56 million, compared to the average estimate of $12.1 million, reflecting a 14.7% year-over-year decline [4] - Net Premiums Earned in Workers Compensation was $41.54 million, close to the average estimate of $41.61 million, showing a minor decrease of 0.5% year-over-year [4] - Net investment income in Segregated Portfolio Cell Reinsurance was $0.9 million, slightly below the average estimate of $0.91 million, with an 8.4% year-over-year decline [4] Stock Performance - ProAssurance shares returned +0.6% over the past month, underperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance in the near term [3]